Showing 351-360 of 4005 results for "".
Arizona - Update in Cardiocerebral Resuscitation, Part 1
https://reachmd.com/programs/grand-rounds-nation/arizona-update-in-cardiocerebral-resuscitation-part-1/6504/Presenting this session of Grand Rounds is Dr. Gordon Ewy, professor and chief of cardiology at the University of Arizona College of Medicine. To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.Arizona - Update in Cardiocerebral Resuscitation, Part 3
https://reachmd.com/programs/grand-rounds-nation/arizona-update-in-cardiocerebral-resuscitation-part-3/6506/Presenting this session of Grand Rounds is Dr. Gordon Ewy, professor and chief of cardiology at the University of Arizona College of Medicine. To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.Vagus Nerve Stimulation Reduced Rescue Medication Use and Decreased Family Burden
https://reachmd.com/programs/practical-neurology/vagus-nerve-stimulation-reduced-rescue-medication-use-and-decreased-family-burden/39913/James Wheless, MD, University of Tennessee Medical Center, Memphis, TN, reports on data demonstrating that using vagus nerve stimulation in patients with drug-resistant epilepsy can reduce rescue medication use, emergency department visits, and hospitalizations while improving patient and family quaRecalibrating Meaningful Use Requirements for Better Clinical Adherence
https://reachmd.com/programs/conversations-on-health-care/recalibrating-meaningful-use-requirements-for-better-clinical-adherence/7208/This week, Mark and Margaret speak with Dr. Peter Basch, a Senior Fellow for Health IT Policy with the Center for American Progress, and a Visiting Scholar with the Engelberg Center for Health Care Reform of the Brookings Institution. He represents the American College of Physicians at the PhysicianEmploying Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
https://reachmd.com/programs/cme/employing-immunotherapy-and-adcs-in-advanced-endometrial-and-cervical-cancers-current-and-emerging-therapies/14460/Our experts are breaking down evolving treatments for advanced endometrial & cervical cancer. Hear the latest data on immunotherapy and ADCs now!Tau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
https://reachmd.com/programs/medical-industry-feature/tau-neurodegeneration-alzheimers-biomarkers/37875/For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau aComprehensive Biomarker Testing in mBC Informs Clinical Decision Making
https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.PI3K Pathway Inhibitors: Safety and Tolerability Profiles
https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.